Literature DB >> 21762285

The impact of mode of acquisition on biological markers of paediatric hepatitis C virus infection.

K England1, C Thorne, H Harris, M Ramsay, M-L Newell.   

Abstract

Despite the introduction of blood donor screening, worldwide, children continue to become infected with hepatitis C virus (HCV) via un-sterile medical injections, receipt of unscreened blood and isolated hospital contamination outbreaks. It is plausible that the natural history and disease progression in these children might differ from that of their vertically infected counterparts. Vertically and parenterally HCV-infected children were prospectively followed within the European Paediatric HCV Network and the UK National HCV Register, respectively. Biological profiles were compared. Vertically and parenterally HCV-infected children differed in terms of some key characteristics including the male to female ratio and the proportion of children receiving therapy. Parenterally infected children were more likely to have at least one hepatomegaly event during follow-up, 20%vs 10%. Parenteral infection did not significantly affect the odds of being consistently viraemic (AOR 1.14, P = 0.703) and there was no significant difference in the odds of having consistently elevated ALT levels and mode of acquisition (AOR 0.83, P = 0.748). The proportion of children with 2 or more markers of HCV infection did not differ significantly by mode of acquisition (χ(2) 1.13, P = 0.288). This analysis does not support substantial differences between vertically and parenterally infected groups, but there are specific mechanisms identified requiring further investigation. Given the continued parenteral infection of children worldwide, it is vital that knowledge of disease progression in this group is accurate and that the differences in comparison with vertically infected children are clarified to inform more accurate and individualized clinical management.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762285      PMCID: PMC3433032          DOI: 10.1111/j.1365-2893.2011.01128.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  28 in total

Review 1.  Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children.

Authors:  Sanguansak Rerksuppaphol; Winita Hardikar; Gregory J Dore
Journal:  J Gastroenterol Hepatol       Date:  2004-12       Impact factor: 4.029

Review 2.  Natural history of hepatitis C.

Authors:  L B Seeff
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

3.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

Authors:  M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

4.  Three broad modalities in the natural history of vertically acquired hepatitis C virus infection.

Authors: 
Journal:  Clin Infect Dis       Date:  2005-05-24       Impact factor: 9.079

5.  Evolution in the hypervariable region of hepatitis C virus in infants after vertical transmission.

Authors:  J Murakami; M Okamoto; H Miyata; I Nagata; K Shiraki; S Hino
Journal:  Pediatr Res       Date:  2000-10       Impact factor: 3.756

6.  Risk of hepatitis C infection in neonates transfused with blood from donors infected with hepatitis C.

Authors:  J M O'Riordan; A Conroy; C Nourse; P L Yap; G S McDonald; G Kaminski; K Leong; E Lawlor; A Davoren; K Strong; F Davidson; A Lloyd; J Power
Journal:  Transfus Med       Date:  1998-12       Impact factor: 2.019

7.  Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000).

Authors:  Simone Ferrero; Pietro Lungaro; Bianca Marisa Bruzzone; Cristina Gotta; Giorgio Bentivoglio; Nicola Ragni
Journal:  Acta Obstet Gynecol Scand       Date:  2003-03       Impact factor: 3.636

8.  Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population.

Authors:  S Paccagnini; N Principi; E Massironi; E Tanzi; L Romanò; M L Muggiasca; M C Ragni; L Salvaggio
Journal:  Pediatr Infect Dis J       Date:  1995-03       Impact factor: 2.129

9.  Smoothing reference centile curves: the LMS method and penalized likelihood.

Authors:  T J Cole; P J Green
Journal:  Stat Med       Date:  1992-07       Impact factor: 2.373

10.  Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Authors:  Thierry Poynard; Vlad Ratziu; John McHutchison; Michael Manns; Zachary Goodman; Stefan Zeuzem; Zobair Younossi; Janice Albrecht
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

View more
  2 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

2.  HCV treatment in children and young adults with HIV/HCV co-infection in Europe.

Authors:  Anna Turkova; Vania Giacomet; Tessa Goetghebuer; Milana Miloenko; Laura Ambra Nicolini; Antoni Noguera-Julian; Pablo Rojo; Alla Volokha; Giuseppe Indolfi; Carlo Giaquinto; Claire Thorne
Journal:  J Virus Erad       Date:  2015-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.